Saturday 17 October 2026
Export VKTX’s income statement to Excel — free account
Viking Therapeutics, Inc.
VKTX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 89.7% and free cash flow fell 166.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
25.17
2.20
−8.04%
Follow VKTX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (88.85%) | (70.04%) | (47.34%) | (29.23%) |
+8 more TTM periods Free account |
|
| (79.24%) | (64.04%) | (44.29%) | (28.31%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(131.11%) | (94.11%) | (56.29%) | (33.31%) | |
Free Cash Flow per Share |
(3.60) | (2.94) | (2.47) | (2.00) | |
Free Cash Flow |
(418.44) | (340.33) | (278.68) | (224.58) | |
| Other line items | |||||
Cash ROIC |
(45.98%) | (30.80%) | (20.72%) | (15.73%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.78 | 0.72 | 0.77 | 0.95 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(3.60) | (2.94) | (2.47) | (2.00) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates